Active, Not Recruiting Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations NCT05364073 Conditions Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more Locations ArriVent Investigative Site — Prescott, Arizona, United States ArriVent Investigative Site — Sacramento, California, United States ArriVent Investigative Site — Whittier, California, United States ArriVent Investigative Site — Celebration, Florida, United States View all 42 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) NCT05607550 Conditions Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more Locations Arrivent Investigative Site — Daphne, Alabama, United States Arrivent Investigative Site — Yuma, Arizona, United States Arrivent Investigative Site — Fayetteville, Arkansas, United States Arrivent Investigative Site — Beverly Hills, California, United States View all 208 locations View more locations Show fewer locations Loading locations... View Trial Details